Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
37 hedge funds and large institutions have $273M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
54% more funds holding
Funds holding: 24 → 37 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less capital invested
Capital invested by funds: $336M → $273M (-$62.5M)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.56M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.69M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.33M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.13M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$865K |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$725K |
| 3 |
Goldman Sachs
New York
|
-$718K |
| 4 |
AG
Artal Group
Luxembourg
|
-$683K |
| 5 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$611K |
KLDO Hedge Fund Activity: Q2 2019 in Review
37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q2 2019, worth a combined $273M — down 19% from $336M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KLDO positions and 7 closed out — a net gain of 13 holders — while 3 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $3.56M. The largest seller was Millennium Management, cutting an estimated $865K.
- 37 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q2 2019, up from 24 in Q1 2019.
- Funds reported $273M of Kaleido Biosciences, Inc. Common Stock stock for Q2 2019, down 19% quarter-over-quarter.
- 20 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q2 2019 and 7 closed out, a net change of +13 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $3.56M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $865K sold.
Based on aggregated 13F filings for Q2 2019.